Sandoz Canada continues to expand its portfolio of generic products
PrSandoz Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.
- Sandoz Canada recently launched PrSandoz® Apixaban SDZ and PrSandoz® Fesoterodine Fumarate.
- PrSandoz® Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.
- Sandoz is the first manufacturer to launch a generic version of PrToviaz®* (PrSandoz® Fesoterodine Fumarate) in Canada, thereby helping to generate substantial savings for patients, hospitals and public and private drug insurance plan providers.
BOUCHERVILLE, Quebec, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. is proud to announce the launch of several products that will expand its portfolio of high-quality generics.
PrSandoz® Apixaban SDZ
PrSandoz® Apixaban SDZ was one of our major launches in 2022. It is a generic equivalent of PrEliquis*, an oral anticoagulant indicated for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of their recurrence.
PrSandoz® Apixaban SDZ is available in strengths of 2.5 mg (bottle of 60 or 500 tablets) and 5 mg (blister pack of 60 tablets and bottle of 180 or 500 tablets).
Over the past five years, the sales volume of Apixaban has increased by more than 15%1, allowing to contribute positively to a growing market. As it is the most prescribed oral anticoagulant in Canada, the launch of PrSandoz® Apixaban SDZ has the potential to generate savings of more than $300 million2 for the healthcare system.
PrSandoz® Fesoterodine Fumarate
PrSandoz® Fesoterodine Fumarate is the first generic equivalent of PrToviaz* available on the Canadian market. It is indicated for the symptomatic treatment of overactive bladder, which is characterized by increased urinary frequency, urinary urgency, incontinence or any combination of these symptoms. It is available in two strengths, 4 mg or 8 mg, each available in bottles of 30 or 100 tablets.
“We are proud to be a major contributor to access to generics in Canada. Sandoz Canada is committed to its role in the healthcare sector and our teams are constantly working to expand our product portfolio to improve patient access to affordable, high-quality medicines. Our products will generate substantial savings that can be reinvested for the benefit of Canadians,” says Michel Robidoux, President and General Manager of Sandoz Canada.
® Trademark owned or used under licence by Sandoz Canada Inc.
* Trademark owned by the registered owner.
Disclaimer
This press release contains forward-looking statements, including, but not limited to, potential future revenues from the sale of PrSandoz® Apixaban SDZ and PrSandoz® Fesoterodine Fumarate. You should not place undue reliance on these statements. These forward-looking statements reflect management's current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results could differ materially from those set forth in the forward-looking statements. There can be no assurance that PrSandoz® Apixaban SDZ and PrSandoz® Fesoterodine Fumarate will be submitted or approved for other additional indications or labelling in other markets, or at any particular time, nor can it be guaranteed that PrSandoz® Apixaban SDZ, PrSandoz® Fesoterodine Fumarate will be approved by a regulatory body or will be commercially successful in the future. In particular, management’s expectations regarding PrSandoz® Apixaban SDZ and PrSandoz® Fesoterodine Fumarate could be affected by a number of factors, including: uncertainties inherent in research and development, including unexpected clinical study results and additional analysis of existing clinical data; unexpected regulatory actions, delays or government regulations in general; the company’s ability to obtain or maintain intellectual property protection; general economic and industry conditions; the global trend towards streamlining healthcare costs, including constant pressure regarding pricing; impacts of the COVID-19 pandemic; unexpected manufacturing problems, and other risks and factors mentioned in form 20-F filed by Novartis AG with the US Securities and Exchange Commission. Sandoz is providing the information in this media release as of today and does not undertake any obligation to update any forward-looking statements described herein as a result of new information, future events or otherwise, except as required by law.
About Sandoz
Sandoz International GmbH is a world leader in generics and biosimilars and a division of the Swiss multinational Novartis.
Sandoz Canada is a pioneer, a leader and trusted supplier of quality generics and biosimilars with over 65 million prescriptions per year, based on decades of global experience and capabilities in the development, manufacturing and commercialization of its products. Sandoz launched the first biosimilar in Europe in 2006 and in the Canadian market in 2009.
www.sandoz.ca
Follow us on LinkedIn: https://www.linkedin.com/company/sandoz-canada/
Contact:
Marie-Soleil Pepin
Sandoz Canada Inc.
+1 438-227-2833
[email protected] / [email protected]
1 Data source: IQVIA CDH MAT Jun-2022
2 Data source: IQVIA CDH MAT Jun-2022
